Attila Sükösd

Ugly Duckling Ventures is a Nordic-focused venture fund investing in early-stage B2B subscription startups with proven revenue, partnering with exceptional founders to help them scale and succeed. We are operational by nature and want to get in the grind as we excel at getting early-stage ventures ready for scale. Being a GP team only, our portfolio founders are never handed off to junior account managers but are directly linked to our experienced partners. We invest in Danish and Nordic B2B subscription startups at the preseed and seed stage; - Initial ticket €0.5-1m - Follow-up thesis: Heavy - Geo: Nordics - Stage: Pre-seed/seed, post revenue (>€200k ARR + traction) - Focus: B2B subscription, open for hardware-enabled SaaS Please dont hesitate to get in touch at hello@uglyduckling.ventures We look forward to hearing from you!

Markster is developing an all-in-one SaaS platform that streamlines essential sales, marketing, and operations tools and resources into a single, user-friendly interface, eliminating the need to learn and manage multiple software solutions. Consciously designed to empower new businesses, startups, solopreneurs, and small businesses to scale and succeed rapidly. The platform offers a comprehensive suite of features, including sales and marketing automation, website and landing page builders, appointment scheduling, CRM, analytics, and a white-label option for agencies. We also provide ready-to-use standard operating procedures (SOPs) and AI-assisted customer support to make the onboarding process smooth and efficient for our users, and their users as well. Our goal is to democratize entrepreneurship by simplifying complex processes, reducing overhead costs, and enabling entrepreneurs to focus on growth and innovation, giving the small players a significant boost in todays competitive landscape.

i1x is not for the faint of heart. Were a venture studio thats on a mission to disrupt the B2B sector and create a new generation of industry leaders. If youre an entrepreneur with a bold vision and an unwavering commitment to success, we want you on our team. By focusing on advanced technologies and adopting a "camel" philosophy, we help founders navigate the challenges of growth and achieve long-term success. Together, well redefine whats possible and build businesses that will shape the future. Connect with us to learn more about our unique approach to venture building.

Ugly Duckling Ventures is a Nordic-focused venture fund investing in early-stage B2B subscription startups with proven revenue, partnering with exceptional founders to help them scale and succeed. We are operational by nature and want to get in the grind as we excel at getting early-stage ventures ready for scale. Being a GP team only, our portfolio founders are never handed off to junior account managers but are directly linked to our experienced partners. We invest in Danish and Nordic B2B subscription startups at the preseed and seed stage; - Initial ticket €0.5-1m - Follow-up thesis: Heavy - Geo: Nordics - Stage: Pre-seed/seed, post revenue (>€200k ARR + traction) - Focus: B2B subscription, open for hardware-enabled SaaS Please dont hesitate to get in touch at hello@uglyduckling.ventures We look forward to hearing from you!

CabinPals is a platform for easily and securely sharing your summer house with friends, family and acquaintances.

We invented a superior diagnostic platform that fast and accurately detects viruses, bacteria or biomarkers. It is our goal to create a business that has a positive impact in the world and helps saving lives. The world needs fast, accurate and affordable diagnostic tools in order to protect and humans’ and animals’ health, and fight infectious diseases. We believe, we can help with that. We work hard to launch the first version of our platform. It is usable within human diagnostics, food safety and veterinary diagnostics. With our ground breaking invention, we will provide our future customers with a technical platform that fast and accurately detects - at their choice - specific viruses, bacteria or biomarkers in any biological fluid.